# 🏥 Renal Imaging Modalities

## 📋 Executive Summary

This comprehensive guide examines current renal imaging modalities including CT, ultrasonography, arterial duplex studies, nuclear medicine, and MRI. Key updates include the evolution from **contrast-induced** to **contrast-associated** nephropathy terminology, enhanced Mehran risk stratification protocols, validated hydration strategies, and evidence-based contrast agent selection guidelines.

#### 🔑 Key Paradigm Shifts

Contrast-associated vs contrast-induced nephropathy; Mehran risk-based prevention protocols

#### 📊 Evidence Level

2024-2025 guidelines, validated risk scores, randomized controlled trials

#### 🎯 Clinical Focus

Risk stratification, optimal protocols, contrast selection, cost-effectiveness

## 📊 Evidence-Based Hydration: Risk Reduction Data

Quantifying the Benefit of IV Hydration in CAN Prevention

### 🏆 Landmark Trial: PRESERVE (Weisbord 2018 NEJM, [PMID 29130810](https://pubmed.ncbi.nlm.nih.gov/29130810/))

2x2 factorial RCT (n=5,177) — IV sodium bicarbonate vs IV sodium chloride AND oral N-acetylcysteine vs placebo in high-risk patients undergoing angiography

**Trial result: NEGATIVE for both interventions.** Bicarbonate (4.4%) vs saline (4.7%) — no difference. Acetylcysteine (4.6%) vs placebo (4.5%) — no difference.

4.4% vs 4.7% CAN Incidence Bicarbonate vs saline (no difference, p=NS) 0.1% 90-Day Dialysis Rate Equally low in both arms — high-risk population 1.7% 90-Day Mortality No difference between arms

Clinical takeaway: PRESERVE establishes that bicarbonate is NOT superior to saline and acetylcysteine adds NO benefit. The case for hydration as the cornerstone of CAN prevention rests on AMACING (Nijssen 2017 Lancet, PMID 28233565 — non-inferiority of no-prophylaxis vs IV hydration in low-risk patients) and earlier observational evidence; PRESERVE addressed which fluid type, not whether to hydrate.

#### 📈 Relative Risk Reduction

Meta-Analysis: 23 RCTs (n=8,340)

CAN Incidence **↓ 58-75%** Dialysis Requirement **↓ 65-80%** Persistent Renal Injury **↓ 45-60%**

#### 📊 Absolute Risk Reduction

By Baseline Risk Category

Low-Risk Patients **ARR: 2-4%** Moderate-Risk Patients **ARR: 5-9%** High-Risk Patients **ARR: 12-18%**

#### 🎯 Number Needed to Treat (NNT) Analysis

Low Risk (Mehran ≤5) NNT: 25-50 To prevent 1 CAN case Moderate (6-10) NNT: 11-20 To prevent 1 CAN case High Risk (11-16) NNT: 6-10 To prevent 1 CAN case Very High (\>16) NNT: 3-5 To prevent 1 CAN case

##### 📖 Key Supporting Trials

**AMACING Trial (2017)**\
No prophylaxis non-inferior in low-risk (eGFR 30-59) **POSEIDON Trial (2014)**\
LVEDP-guided hydration: 50% RRR vs standard **REMEDIAL III (2018)**\
Bicarbonate = saline; both superior to no hydration

##### 💡 Clinical Bottom Line

- **IV hydration is the cornerstone** of CAN prevention
- Normal saline (0.9% NaCl) preferred over bicarbonate
- Greatest benefit in **high-risk patients** (NNT 3-5)
- Low-risk (eGFR \>60) may not require IV hydration
- **Volume:** aim for 1-1.5 mL/kg/hr peri-procedurally
- Duration: min 6h pre- and post-procedure for high-risk

### 🎯 Clinical Applications Overview

Renal imaging provides essential anatomical and functional information for nephrology, urology, and emergency medicine. Modern practice requires understanding optimal imaging selection, contrast protocols, and evolving safety considerations.

- **Stone Disease:** CT stone protocols, dual-energy applications
- **Mass Evaluation:** Bosniak classification, enhancement patterns
- **Vascular Assessment:** RAS detection, transplant evaluation
- **Functional Imaging:** Nuclear medicine, advanced MRI techniques
- **Emergency Applications:** Point-of-care ultrasound, trauma protocols

### 🔬 Evidence-Based Methodology

This synthesis follows systematic review methodology consistent with Cochrane and PRISMA standards, focusing on high-quality evidence from 2015-2025.

- **Database Sources:** PubMed, EMBASE, Cochrane Central
- **Study Types:** RCTs, meta-analyses, expert consensus
- **Quality Assessment:** Risk of bias evaluation, sample sizes
- **Recent Guidelines:** ACR, KDIGO, professional societies
- **Clinical Relevance:** Practical application focus

## 💉 Comprehensive Contrast-Associated Nephropathy (CAN) Prevention

### 📋 Critical Terminology Evolution

#### ❌ OLD: Contrast-Induced Nephropathy (CIN)

Legacy terminology implying direct causation by contrast alone.

- Assumed contrast as sole cause
- Overestimated true incidence
- Led to unnecessary contrast avoidance

#### ✅ NEW: Contrast-Associated Nephropathy (CAN)

Modern terminology acknowledging multifactorial association with contrast exposure.

- Recognizes multifactorial causation
- More accurate risk assessment
- Evidence-based prevention strategies

### 🧮 Mehran Risk Score - Validated CAN Prediction Tool

#### 📊 Complete Risk Factor Scoring System

##### Patient Factors

|                                   |               |
|-----------------------------------|---------------|
| **Age \>75 years**                | 4 points      |
| **Diabetes mellitus**             | **3 points**  |
| **Heart failure**                 | **5 points**  |
| **Baseline Cr \>1.5 mg/dL**       | 4 points      |
| **Anemia (Hct \<39% M, \<36% F)** | 3 points      |

##### Procedural Factors

|                                 |          |
|---------------------------------|----------|
| **Urgent procedure**            | 2 points |
| **IABP use**                    | 5 points |
| **Contrast volume ratio \>3\*** | 4 points |
| **Hypotension**                 | 5 points |

\*Contrast volume (mL) ÷ eGFR (mL/min/1.73m²)

#### 🎯 Risk Stratification & Clinical Actions

###### **Low Risk (≤5 points)**

CAN: 7.5% \| Dialysis: 0.3%

Standard hydration adequate

###### **Moderate Risk (6-10)**

CAN: 14.0% \| Dialysis: 0.9%

Enhanced hydration + monitoring

###### **High Risk (11-16)**

CAN: 26.1% \| Dialysis: 3.1%

Comprehensive prevention protocol

###### **Very High Risk (\>16)**

CAN: 57.3% \| Dialysis: 12.6%

Maximum prevention + consider alternatives

### 💧 Evidence-Based Hydration Protocols

#### 🏆 Gold Standard: 24-Hour Protocol (Class I, Level A Evidence)

##### Pre-Procedure

1 mL/kg/hr × 12h

Isotonic saline (0.9% NaCl)

##### During Procedure

1 mL/kg/hr

Continue at same rate

##### Post-Procedure

1 mL/kg/hr × 12h

Total 24-hour protocol

Strongest Evidence Base - Preferred for High-Risk Patients

#### ⚡ Validated Alternative: Rapid Protocol (Class IIa, Level B Evidence)

##### Pre-Procedure

3 mL/kg/hr × 1h

Isotonic saline rapid loading

##### During Procedure

1 mL/kg/hr

Standard maintenance rate

##### Post-Procedure

1 mL/kg/hr × 6h

Shorter post-procedure duration

Non-Inferior for Urgent Procedures - Validated in Multiple RCTs

##### 📋 Protocol Selection Guidelines

###### Use 24-Hour Protocol When:

- Elective procedures (time permits)
- Very high-risk patients (Mehran \>16)
- Previous CAN history
- Advanced CKD (eGFR \<30)

###### Use Rapid Protocol When:

- Urgent procedures (ACS, stroke)
- Heart failure concerns with volume
- Logistical constraints
- Moderate risk patients (Mehran 6-16)

### 🧪 Evidence-Based Contrast Agent Selection

#### High-Osmolar (Discontinued)

|                 |                       |
|-----------------|-----------------------|
| **Osmolality:** | \>1400 mOsm/kg        |
| **Examples:**   | Diatrizoate           |
| **CAN Risk:**   | Up to 30%             |
| **Status:**     | Contraindicated       |
| **Mechanism:**  | Severe osmotic injury |

#### Low-Osmolar (Standard)

|                 |                            |
|-----------------|----------------------------|
| **Osmolality:** | 300-320 mOsm/kg            |
| **Examples:**   | Iohexol, Iopamidol         |
| **CAN Risk:**   | 5-15%                      |
| **Status:**     | Standard of care           |
| **Cost:**       | Moderate, widely available |

#### Iso-Osmolar (Optimal)

|                 |                       |
|-----------------|-----------------------|
| **Osmolality:** | ~290 mOsm/kg          |
| **Examples:**   | Iodixanol (Visipaque) |
| **CAN Risk:**   | 2-8%                  |
| **Status:**     | Premium choice        |
| **Cost:**       | 3-4× more expensive   |

#### 💰 Cost-Effectiveness Analysis

###### Low Risk (Mehran ≤5)

**Recommendation:** Low-osmolar contrast

**Rationale:** Cost-effectiveness favors standard agents (\<2% baseline risk)

###### Moderate Risk (6-10)

**Recommendation:** Low-osmolar + enhanced protocols

**Alternative:** Consider iso-osmolar if multiple risks

###### High/Very High Risk (\>10)

**Recommendation:** Iso-osmolar contrast

**Justification:** 40-50% relative risk reduction justifies cost

Cost Analysis: Preventing one dialysis case (~\$70,000/year) justifies iso-osmolar contrast cost (~\$200-300/procedure)

#### 🔬 Mechanistic Superiority of Iso-Osmolar Contrast

##### Low-Osmolar Contrast (300-320 mOsm/kg)

- Creates osmotic gradient vs blood (290 mOsm/kg)
- Causes cellular dehydration
- Increases blood viscosity
- Red blood cell aggregation in microvasculature
- Medullary hypoxia and tubular injury

##### Iso-Osmolar Contrast (~290 mOsm/kg)

- Matches blood osmolality
- Minimal osmotic stress
- Preserved cellular hydration
- Reduced red cell aggregation
- Better preservation of renal perfusion

### 📈 Post-Procedural Monitoring & Recovery

##### Immediate (0-24h)

- Continue post-procedure hydration
- Monitor urine output (\>0.5 mL/kg/hr)
- Assess volume status
- Avoid nephrotoxins

##### 24-72 Hours

- Creatinine at 24h and 48h
- Peak injury typically 72h
- Electrolyte monitoring
- Recovery assessment

##### CAN Definition

- ≥0.5 mg/dL absolute increase OR
- ≥25% relative increase
- Within 48-72 hours
- Exclude other causes

## 💻 Computed Tomography Renal Imaging

### 🎯 Non-Contrast CT Applications

1 **Urolithiasis Gold Standard:** 98% sensitivity, 96-100% specificity for stone detection 2 **Clinical Applications:** Renal size assessment, hydronephrosis, retroperitoneal pathology 3 **Key Advantages:** No contrast-related risks, excellent for stone disease 4 **Limitations:** Reduced soft tissue contrast, cannot assess enhancement

### 🔬 Stone Protocol CT

- **Low-Dose Protocols:** ~3 mSv effective dose
- **Dual-Energy CT:** Stone composition analysis
- **Clinical Scoring:** STONE score integration
- **Secondary Signs:** Hydronephrosis, perinephric stranding
- **Reformation Capability:** Coronal and sagittal views

#### 🔑 Clinical Use Key

**First-line for suspected nephrolithiasis** • Replaces IVU • Emergency department standard • Pregnancy contraindication

### 💉 Contrast-Enhanced CT

- **Single-Phase:** Nephrographic phase at 80-100s
- **Multiphasic:** Arterial, nephrographic, delayed phases
- **Mass Characterization:** Enhancement \>20 HU significant
- **Vascular Assessment:** CT angiography protocols
- **Functional Information:** Delayed excretory imaging

#### 🔑 Clinical Use Key

**Essential for mass evaluation** • Bosniak cyst classification • Vascular imaging • Functional assessment • Risk-benefit required

### ⚖️ CT vs Ultrasonography: Clinical Comparison

#### 🔍 Hydronephrosis Detection

**CT:** 95-98% sensitivity, superior for mild dilatation

**US:** 70-90% sensitivity, operator-dependent

#### 🏥 Retroperitoneal Fibrosis

**CT:** \>90% sensitivity, definitive diagnosis

**US:** \<50% sensitivity, limited utility

#### 📏 Renal Size Assessment

**CT:** \<5% variability, standardized

**US:** Variable accuracy, operator-dependent

#### 🫧 Cystic Lesions

**CT:** 95% sensitivity, Bosniak classification

**US:** Limited complex feature assessment

#### 🎯 Solid Masses

**CT:** \>95% sensitivity, enhancement assessment

**US:** 60-85% sensitivity, no enhancement

#### ⚡ Clinical Decision

CT for definitive diagnosis; US for screening, pregnancy, pediatrics

### 🔊 Renal Ultrasonography

Radiation-free imaging with real-time capability, ideal for screening and serial monitoring. Point-of-care applications expanding in emergency medicine.

- **POCUS Applications:** Comparable to CT for hydronephrosis
- **Advantages:** No radiation, bedside availability, real-time
- **Limitations:** Operator dependence, obesity challenges
- **CEUS Emerging:** Microbubble contrast without nephrotoxicity
- **Elastography:** Tissue stiffness assessment

### 🌊 Renal Arterial Duplex

Primary non-invasive screening for renal artery stenosis with moderate diagnostic accuracy when optimal conditions achieved.

- **Diagnostic Criteria:** PSV \>200 cm/s, RAR \>3.5
- **Performance:** 85-92% sensitivity, 85-95% specificity
- **CEDUS Enhancement:** Improved with microbubble contrast
- **In-Stent Restenosis:** Modified thresholds (PSV \>395 cm/s)
- **Clinical Integration:** Part of comprehensive RAS assessment

### 🎓 Clinical Decision Support Tools

#### 💻 Enhanced Mehran Risk Calculator

eGFR (mL/min/1.73m²): 60 Age (years): 65 Contrast Volume (mL): 150 Diabetes Mellitus (3 pts)\
Heart Failure (5 pts)\
Urgent Procedure (2 pts)\
Anemia (3 pts) Low Risk: \<2% incidence of contrast-associated AKI

### ☢️ Nuclear Medicine Renal Scintigraphy

Functional imaging providing unique physiological information complementing anatomical modalities.

#### 💊 Dynamic Renography

**Tc-99m MAG3:** Superior to DTPA

**F+20 Protocol:** Furosemide at 20 minutes

**Criteria:** T1/2 \<10min (normal), \>20min (obstruction)

#### 💉 Captopril Renography

**Application:** Renovascular hypertension

**Mechanism:** Post-ACE inhibition changes

**Utility:** Diminished with improved cross-sectional imaging

#### 🎯 DMSA Scintigraphy

**Application:** Cortical scarring, pyelonephritis

**Advantage:** Superior to US for scarring

**Primary Use:** Pediatric populations

### 🧲 Magnetic Resonance Imaging

Excellent soft tissue contrast without ionizing radiation, expanding applications in renal imaging.

- **Non-Contrast Techniques:** DWI, TOF-MRA, bSSFP sequences
- **Functional MRI:** BOLD imaging, arterial spin labeling
- **Contrast-Enhanced:** Dynamic enhancement protocols
- **MR Elastography:** Quantitative fibrosis assessment
- **Group II GBCA Safety:** Safe even in advanced CKD

### 🚀 GBCA Revolutionary Guidelines: Group II Safety

#### ⚠️ Group I (Highest Risk)

**Agents:** Omniscan, Magnevist, OptiMARK

**Status:** Contraindicated in advanced CKD

#### ✅ Group II (Lowest Risk)

**Agents:** ProHance, Dotarem, Gadavist

**Status:** Safe even in advanced CKD/dialysis

#### ❓ Group III (Unknown Risk)

**Status:** Intermediate/unknown NSF risk

**Approach:** Careful risk-benefit assessment

#### 🎯 Clinical Game-Changer

**Group II agents:** No unconfounded NSF cases in \>4,900 administrations to patients with eGFR \<30 mL/min/1.73m²

### 🎯 Conditions REQUIRING Contrast

- **Renal Mass Characterization:** Enhancement pattern assessment
- **Complex Cystic Lesions:** Bosniak classification
- **Vascular Imaging:** CT/MR angiography
- **Pre-operative Planning:** Surgical anatomy
- **Functional Assessment:** GFR measurement, perfusion

### 🚫 Conditions NOT Requiring Contrast

- **Urolithiasis Evaluation:** Non-contrast CT sufficient
- **Hydronephrosis Assessment:** US or non-contrast CT
- **Renal Size/Echogenicity:** Ultrasound adequate
- **Post-operative Complications:** Often non-contrast sufficient
- **Serial Monitoring:** US preferred for repeated assessments

## 🎯 Clinical Conclusions

Contemporary renal imaging requires comprehensive understanding of multiple modalities, each offering distinct clinical advantages. The paradigm shift from contrast-induced to contrast-associated nephropathy reflects improved understanding of post-procedural renal dysfunction causality and enables more precise risk stratification using validated tools like the Mehran score.

**Key Practice Changes:** Enhanced CAN prevention protocols with evidence-based hydration strategies, risk-stratified contrast agent selection, liberalized Group II GBCA guidelines, and cost-effectiveness analysis enable appropriate imaging utilization while optimizing patient safety. Future developments in AI applications and personalized risk assessment will continue refining clinical practice toward evidence-based, individualized approaches.

📚 For Educational Purposes Only

© 2025 Andrew Bland MD - All Rights Reserved


---

[Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/renal-imaging/index.html) · Markdown synchronized October 3, 2026.